SCHEMBL368717

SCHEMBL368717

COc1ncc(-c2ccc3ncc4c(c3c2)n(-c2ccc(C(C)(C)C#N)cc2)c(=NC#N)n4C)cc1NS(=O)(=O)c1ccc(F)cc1F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 5/20 0.53
PI4KA P42356 2/20 0.53
PIK3CA P42336 18/20 0.52
PIK3R1 P27986 8/20 0.51
MTOR P42345 6/20 0.51
PIK3CD O00329 3/20 0.49
PIK3CB P42338 3/20 0.49
PRKDC P78527 2/20 0.49
RPTOR Q8N122 2/20 0.49
PIK3C3 Q8NEB9 2/20 0.49
MLST8 Q9BVC4 2/20 0.49
PDE4D Q08499 1/20 0.49
RICTOR Q6R327 1/20 0.49
PIP4K2C Q8TBX8 1/20 0.49
MAPKAP1 Q9BPZ7 1/20 0.49
IRAK3 Q9Y616 1/20 0.49
PIK3C2A O00443 1/20 0.49
PIK3C2B O00750 1/20 0.49
CHEK1 O14757 1/20 0.49
ABCB11 O95342 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL368716 1.00 PIK3CG (0.53) PIK3CGPI4KAPIK3CAPIK3R1MTOR
SCHEMBL368101 0.90 PIK3CA (0.54) PIK3CGPI4KAPIK3CAPIK3R1MTOR
SCHEMBL369458 0.90 PIK3CA (0.54) PIK3CGPI4KAPIK3CAPIK3R1MTOR
SCHEMBL367906 0.89 PIK3CG (0.54) PIK3CGPI4KAPIK3CAPIK3R1MTOR
SCHEMBL367861 0.89 PIK3CG (0.54) PIK3CGPI4KAPIK3CAPIK3R1MTOR
SCHEMBL367692 0.82 PIK3CG (0.52) PIK3CGPI4KAPIK3CAPIK3R1MTOR
SCHEMBL14913991 0.82 PIK3CG (0.52) PIK3CGPI4KAPIK3CAPIK3R1MTOR
SCHEMBL367189 0.82 PIK3CD (0.51) PIK3CGPI4KAPIK3CAPIK3R1MTOR
SCHEMBL368220 0.82 PIK3CA (0.56) PIK3CGPIK3CAPIK3R1MTORPIK3CD
SCHEMBL14914937 0.82 PIK3CA (0.56) PIK3CGPIK3CAPIK3R1MTORPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9062046-B2 Substituted imidazoquinoline derivatives as kinase inhibitors Piramal Enterprises Limited (IN) 2015-06-23 US claimed
US-20130116248-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS Piramal Enterprises Limited (IN) 2013-05-09 US claimed
US-9062046-B2 Substituted imidazoquinoline derivatives as kinase inhibitors Piramal Enterprises Limited (IN) 2015-06-23 US disclosed
EP-2593450-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS Piramal Enterprises Limited (IN) 2013-05-22 EP disclosed
US-20130116248-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS Piramal Enterprises Limited (IN) 2013-05-09 US disclosed
WO-2012007926-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116248-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS CDK2, CDK4, MAP3K1 PIK3CG 139/4885PI4KA 91/4885PIK3CA 72/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.